Related Experiment Video
Updated: Jun 27, 2025
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Plasma SMOC2 Predicts Prognosis in Patients with Heart Failure: A Prospective Cohort
Xin Chen1,2,3, Xing Zhong1,4, Dan Luo1,2,3
1Cardiovascular Disease Center, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, Hubei Province, People's Republic of China.
Insights
Secreted modular calcium-binding protein 2 (SMOC2) levels in heart failure (HF) patients correlate with disease severity and hospital readmission risk. Higher SMOC2 indicates a greater likelihood of readmission, suggesting its potential as a predictive biomarker.
Area of Science:
- Cardiology
- Biomarker Discovery
- Clinical Research
Background:
- Heart failure (HF) is a chronic condition with significant prognostic implications.
- Secreted modular calcium-binding protein 2 (SMOC2) has a known role in cardiac fibrosis.
- The clinical utility of SMOC2 as a prognostic marker in HF patients requires investigation.
Purpose of the Study:
- To evaluate the association between plasma SMOC2 levels and prognosis in patients with heart failure.
- To determine if SMOC2 can serve as a clinical marker for HF patient outcomes.
Main Methods:
- 188 patients with ischemic cardiomyopathy were enrolled.
- Baseline plasma SMOC2 levels were measured alongside clinical data.
- Multivariate Cox regression models analyzed the relationship between SMOC2 and patient outcomes.
Main Results:
- Plasma SMOC2 positively correlated with NT-proBNP, LVEDd, and hospital stay duration.
- SMOC2 negatively correlated with LVEF.
- Elevated SMOC2 levels were significantly associated with increased risk of HF readmission (HR=1.02).
Conclusions:
- Plasma SMOC2 is linked to HF severity and readmission rates.
- SMOC2 demonstrates potential as a predictive biomarker for HF readmission risk.
Background:
Heart failure (HF) is a chronic disease with a poor prognosis, making it extremely important to assess the prognosis of patients with HF for accurate treatment. Secreted modular calcium-binding protein 2 (SMOC2) is a cysteine-rich acidic secreted protein that plays a pathophysiological role in many diseases, including regulation of vascular growth factor activity. It has previously been found that SMOC2 plays an essential role in cardiac fibrosis in our previous preclinical study, but whether it can be used as a clinical marker in heart failure patients remains unclear. The purpose of this research was to evaluate the correlation between plasma levels of SMOC2 and the prognosis for individuals with HF.
Methods:
HF patients diagnosed with ischemic cardiomyopathy were enrolled from January to December 2021. Baseline plasma levels of SMOC2 were measured after demographic and clinical features were collected. Linear and nonlinear multivariate Cox regression models were used to determine the association between plasma SMOC2 and patient outcomes during follow-up. All analysis was performed using SPSS, EmpowerStats, and R software.
Results:
The study included 188 patients, and the average follow-up time was 489.5±88.3 days. The plasma SMOC2 concentrations were positively correlated with N-terminal pro-B-type Natriuretic Peptide (NT-proBNP), left ventricular end-diastolic diameter (LVEDd), and length of hospital stay and were negatively correlated with left ventricular ejection fraction (LVEF) at baseline. A total of 53 patients (28.2%) were rehospitalized due to cardiac deterioration, 14 (7.4%) died, and 37 (19.7%) developed malignant arrhythmias. A fully adjusted multivariate COX regression model showed that SMOC2 is associated with readmission (HR = 1.02, 95% CI:1.012-1.655). A significant increase in rehospitalization risk was observed in group Q2 (HR =1.064, 95% CI: 1.037, 3.662, p=0.005) and group Q3 (HR =1.085, 95% CI:1.086, 3.792, p=0.009) in comparison with group Q1. The p for trend also shows a linear correlation across the three models (P < 0.001). SMOC2 was associated with the severity of HF in patients, but not with all-cause deaths and arrhythmias during follow-up.
Conclusion:
Plasma SMOC2 is associated with the severity of HF and readmission rate, and is a good predictor of the risk of readmission in patients.
More Related Videos
07:25Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
Published on: September 22, 2020
04:20Integration of Brain Tissue Saturation Monitoring in Cardiopulmonary Exercise Testing in Patients with Heart Failure
Published on: October 1, 2019
